English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/63330
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Therapeutic potential of CB2 targeting in multiple sclerosis

AuthorsDocagne, Fabian ; Mestre, Leyre ; Loría, Frida ; Hernangómez-Herrero, Miriam ; Correa, Fernando Gabriel ; Guaza, Carmen
CB2 receptor
Multiple sclerosis
Theiler's murine encephalomyelitis virus
Issue Date2008
PublisherAshley Publications
CitationExpert Opinion on Therapeutic Targets 12(2): 185-195 (2008)
AbstractBackground: Cannabinoids have been shown to exert beneficial actions in different animal models of multiple sclerosis (MS). However, the use of cannabinoids compounds in human therapy is greatly limited by their psychoactivity. Thus, new hopes in MS therapy have arisen from the evidence for a cannabinoid receptor, termed CB2, which is devoid of psychoactive effects in animal models. Objective: This review discusses the different mechanisms by which CB2 activation could induce therapeutic actions in MS. Methods: Particular focus is given to the potential effects on inflammation/autoimmunity, remyelination and neuroprotection. Conclusion: This review discusses the importance of glial cells in sustaining these effects, as well as the putative secondary effects that would limit the use of CB2 agonists in the treatment of MS. © 2008 Informa UK Ltd.
Publisher version (URL)http://doi.org/10.1517/14728222.12.2.185
Identifiersdoi: 10.1517/14728222.12.2.185
issn: 1472-8222
Appears in Collections:(IC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.